AR068438A1 - Derivado de 6-pirimidinil-pirimid-2-ona - Google Patents
Derivado de 6-pirimidinil-pirimid-2-onaInfo
- Publication number
- AR068438A1 AR068438A1 ARP080103981A ARP080103981A AR068438A1 AR 068438 A1 AR068438 A1 AR 068438A1 AR P080103981 A ARP080103981 A AR P080103981A AR P080103981 A ARP080103981 A AR P080103981A AR 068438 A1 AR068438 A1 AR 068438A1
- Authority
- AR
- Argentina
- Prior art keywords
- pirimid
- pirimidinil
- ona
- derived
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto representado por la formula (1) o una sal farmacéuticamente aceptable de él, que se usa para el tratamiento preventivo y/o terapéutico de una enfermedad provocada por la actividad anormal de la tau proteína cinasa 1 tal como enfermedades neurodegenerativas (por ejemplo, la enfermedad de Alzheimer).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007269484 | 2007-09-14 | ||
JP2007275714 | 2007-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR068438A1 true AR068438A1 (es) | 2009-11-18 |
Family
ID=40085496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103981A AR068438A1 (es) | 2007-09-14 | 2008-09-12 | Derivado de 6-pirimidinil-pirimid-2-ona |
Country Status (14)
Country | Link |
---|---|
US (1) | US8288383B2 (es) |
EP (1) | EP2197877B1 (es) |
JP (1) | JP5449147B2 (es) |
KR (1) | KR20100074183A (es) |
CN (1) | CN101842371A (es) |
AR (1) | AR068438A1 (es) |
AU (1) | AU2008297814A1 (es) |
BR (1) | BRPI0816708A2 (es) |
CA (1) | CA2698818A1 (es) |
EA (1) | EA201070366A1 (es) |
MX (1) | MX2010002766A (es) |
TW (1) | TW200927133A (es) |
WO (1) | WO2009035159A1 (es) |
ZA (1) | ZA201002214B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200813015A (en) * | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
AR064660A1 (es) | 2006-12-26 | 2009-04-15 | Mitsubishi Tanabe Pharma Corp | Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras |
US8940738B2 (en) | 2009-08-13 | 2015-01-27 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone compounds |
WO2012007426A1 (en) | 2010-07-13 | 2012-01-19 | Basf Se | Azoline substituted isoxazoline benzamide compounds for combating animal pests |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2802578B1 (en) | 2012-01-12 | 2015-10-07 | F.Hoffmann-La Roche Ag | Heterocyclic derivatives as trace amine associated receptors (taars) |
ES2637245T3 (es) | 2012-06-29 | 2017-10-11 | Pfizer Inc. | Nuevas 4-(amino sustituido)-7H-pirrolo[2,3-d]pirimidinas como inhibidores de LRRK2 |
US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
JP6873980B2 (ja) | 2015-09-14 | 2021-05-19 | ファイザー・インク | LRRK2阻害薬としての新規のイミダゾ[4,5−c]キノリンおよびイミダゾ[4,5−c][1,5]ナフチリジン誘導体 |
CN113831296B (zh) * | 2021-07-27 | 2023-07-21 | 北京理工大学 | 1-苯基-3-(4-(嘧啶-5-基氨基)苯基)丙-2-烯-1-酮类化合物及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4368682B2 (ja) | 2001-09-21 | 2009-11-18 | 田辺三菱製薬株式会社 | 3−置換−4−ピリミドン誘導体 |
WO2003037888A1 (en) * | 2001-09-21 | 2003-05-08 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
-
2008
- 2008-09-12 CA CA2698818A patent/CA2698818A1/en not_active Abandoned
- 2008-09-12 CN CN200880113745A patent/CN101842371A/zh active Pending
- 2008-09-12 EA EA201070366A patent/EA201070366A1/ru unknown
- 2008-09-12 JP JP2010510583A patent/JP5449147B2/ja not_active Expired - Fee Related
- 2008-09-12 WO PCT/JP2008/066929 patent/WO2009035159A1/en active Application Filing
- 2008-09-12 AU AU2008297814A patent/AU2008297814A1/en not_active Abandoned
- 2008-09-12 KR KR1020107008068A patent/KR20100074183A/ko not_active Application Discontinuation
- 2008-09-12 EP EP08830245.0A patent/EP2197877B1/en active Active
- 2008-09-12 US US12/677,161 patent/US8288383B2/en not_active Expired - Fee Related
- 2008-09-12 MX MX2010002766A patent/MX2010002766A/es not_active Application Discontinuation
- 2008-09-12 AR ARP080103981A patent/AR068438A1/es not_active Application Discontinuation
- 2008-09-12 BR BRPI0816708 patent/BRPI0816708A2/pt not_active IP Right Cessation
- 2008-09-12 TW TW097135151A patent/TW200927133A/zh unknown
-
2010
- 2010-03-29 ZA ZA2010/02214A patent/ZA201002214B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010538970A (ja) | 2010-12-16 |
WO2009035159A1 (en) | 2009-03-19 |
ZA201002214B (en) | 2011-06-29 |
BRPI0816708A2 (pt) | 2015-03-17 |
MX2010002766A (es) | 2010-05-19 |
US20110003988A1 (en) | 2011-01-06 |
JP5449147B2 (ja) | 2014-03-19 |
US8288383B2 (en) | 2012-10-16 |
KR20100074183A (ko) | 2010-07-01 |
TW200927133A (en) | 2009-07-01 |
EP2197877B1 (en) | 2013-05-15 |
EP2197877A1 (en) | 2010-06-23 |
WO2009035159A8 (en) | 2010-07-29 |
AU2008297814A1 (en) | 2009-03-19 |
CA2698818A1 (en) | 2009-03-19 |
EA201070366A1 (ru) | 2010-08-30 |
CN101842371A (zh) | 2010-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR068438A1 (es) | Derivado de 6-pirimidinil-pirimid-2-ona | |
DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
AR111693A1 (es) | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga | |
AR068439A1 (es) | Derivado de 6-pirimidinil-pirimid-2-ona | |
SV2006002055A (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a | |
EA201891703A1 (ru) | Соединения бензопиразола и их аналоги | |
EA200901373A1 (ru) | Аминогетероциклические соединения | |
BRPI0513433A (pt) | derivados de hidantoìna para o tratamento de distúrbios inflamatórios | |
AR059948A1 (es) | Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa | |
NO20090755L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
CL2007002288A1 (es) | Compuestos derivados de imidazol-amina condensados, inhibidores de la beta-secretasa; proceso de preparacion; composicion farmaceutica, util para el tratamiento, prevencion o mejoramiento de enfermedades tales como enfermedad de alzheimer, deterioro | |
EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
UA114726C2 (uk) | 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів | |
NO20090166L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
CL2008000946A1 (es) | Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun | |
BRPI0515851A (pt) | composto de pirimidona | |
EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
UY30377A1 (es) | Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa | |
MX346186B (es) | Inhibidores de proteina cinasas. | |
CL2008001960A1 (es) | Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide. | |
EA201270359A1 (ru) | Терапевтическое средство от расстройств настроения | |
UY28825A1 (es) | Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos | |
BR112014008783A2 (pt) | compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório | |
CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
HK1110211A1 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |